Paper Details

  1. Home
  2. Paper Details

Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis.

Author: FredianiB, GigliucciG, IntegliaD, IsailovicN, MiglioreA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting the spine. This study will compare the effects and safety of different biologic medications used to treat AS: adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, and secukinumab. The goal is to understand the differences between these medications.
Paper Details　
Original Abstract of the Article :
Ankylosing Spondylitis (AS) is a chronic form of arthritis of unknown origin affecting the spine. In this study, we aimed to identify clinical and safety profiles of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, and secukinumab that are biologic agents (biologics) mainly used fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.26355/eurrev_202101_24347

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Ankylosing Spondylitis Treatment: A Comprehensive Analysis of Biologics

The treatment of ankylosing spondylitis (AS) often feels like navigating a desert of uncertainty, with patients seeking a stable oasis of relief. This study provides a comprehensive analysis of the clinical and safety profiles of various biologics used to treat AS, offering valuable insights into the treatment landscape. The researchers employed network meta-analysis to compare the effectiveness and safety of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, and secukinumab, providing a more nuanced understanding of their individual characteristics.

A Deeper Understanding of the Desert: Exploring the Clinical and Safety Profiles of Biologics

The study provides a detailed analysis of the clinical and safety profiles of various biologics used to treat AS, offering valuable insights into their individual characteristics and allowing for a more informed selection of treatment options. This study highlights the importance of individualized care and the need to consider both efficacy and safety profiles when selecting biologics for AS treatment.

Navigating the Desert of AS Treatment: A Guide to Informed Decision-Making

This study empowers healthcare providers to make informed decisions about biologic treatment for AS, taking into account the unique characteristics of each agent and the specific needs of the individual patient. This research contributes to a more comprehensive understanding of the landscape of AS treatment, potentially leading to more effective and personalized approaches.

Dr.Camel's Conclusion

This study provides a valuable tool for navigating the complex landscape of AS treatment, offering a deeper understanding of the clinical and safety profiles of various biologics. By carefully considering these insights and prioritizing individualized care, healthcare professionals can help patients find their own personal oasis of relief in the desert of AS.

Date :
  1. Date Completed 2021-06-29
  2. Date Revised 2021-06-29
Further Info :

Pubmed ID

33506892

DOI: Digital Object Identifier

10.26355/eurrev_202101_24347

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.